Genprex announced that the Korean Patent Office has issued a Notice of Patent Grant for a broad patent that covers the use of Genprex’s lead drug candidate, Reqorsa Immunogene Therapy, in combination with anti-PD-1 and PD-L1 antibodies through 2037. This patent will expand on the previously granted patents in the U.S., Japan, Mexico, Russia, Australia, Chile and China to cover the use of REQORSA in combination with immune checkpoint inhibitors, e.g., PD-1 and PD-L1 inhibitors. These patents are applicable to Genprex’s Acclaim-2 and Acclaim-3 clinical trials.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on GNPX: